New Study Reveals Antipsychotics' Impact on Visuospatial Memory in Healthy Volunteers

Are Antipsychotics Impairing Visuospatial Memory?

Amisulpride and aripiprazole impair visuospatial working memory in healthy volunteers, a new study finds. Researchers at a UK academic center have demonstrated that both a D2/D3 receptor antagonist and a D2/D3 partial agonist significantly impact cognitive function after sustained administration, with particular effects on working memory response times rather than accuracy. The findings have implications for the millions of patients worldwide taking these medications chronically.

How Was the Cognitive Study Designed?

In what is described as the first study of its kind, investigators administered either amisulpride (titrated to 400 mg/day) or aripiprazole (titrated to 10 mg/day) to healthy volunteers for seven days in a double-blind, placebo-controlled crossover design. The study specifically measured visuospatial working memory (VS-WM), sustained attention, and response inhibition – cognitive domains known to be affected in conditions like schizophrenia and Parkinson's disease, where dopaminergic dysfunction plays a central role. Rather than testing in patient populations where disease processes could confound results, the researchers used healthy volunteers to isolate the direct effects of the medications.

The findings revealed a specific pattern of cognitive effects. Neither drug impaired sustained attention or response inhibition, but both significantly affected VS-WM performance. Notably, this impairment manifested as increased response latency rather than reduced accuracy – suggesting participants were slowing down to maintain performance quality. "What we're seeing is evidence of altered speed-accuracy trade-offs following sustained D2/D3 receptor modulation," explained a senior researcher involved in the study. "This provides the first causative evidence in humans that visuospatial working memory is impaired following sustained antagonism or partial agonism of D2/D3 receptors by antipsychotics."

Do the Results Challenge Traditional Assumptions?

This research addresses a longstanding question in psychopharmacology regarding the cognitive effects of antipsychotic medications. While patients frequently report subjective cognitive "slowing" during chronic antipsychotic treatment – often leading to treatment discontinuation – previous acute-dosing studies in healthy volunteers have shown mixed results. By administering the drugs for a full week, this study bridges the gap between single-dose experiments and the clinical experience of long-term users. The doses selected for both medications represent the minimum clinically effective doses used in schizophrenia treatment, making the findings directly relevant to standard clinical practice.

Contrary to industry expectations, the researchers found that aripiprazole, despite its partial agonist mechanism that has been hypothesized to cause fewer cognitive side effects, produced working memory impairments of similar magnitude to the full antagonist amisulpride. This challenges the prevailing assumption that partial agonists inherently preserve cognitive function better than antagonists. However, exploratory analyses suggested some nuance – aripiprazole impaired performance only in more difficult variable-location trials, while amisulpride caused impairments across both simple and complex trial types.

What Do Detailed Cognitive Assessments Reveal?

The pharmaceutical industry has increasingly focused on developing antipsychotics with improved side effect profiles, including reduced cognitive burden. Companies like Alkermes, Karuna Therapeutics, and Cerevel have been developing agents with novel mechanisms or selective receptor targeting aiming to minimize these effects. This study's findings may influence how these development programs assess cognitive outcomes and differentiate their products.

The study also included measurements of subjective effects and parkinsonian symptoms. Interestingly, despite objective cognitive changes, participants did not report subjective changes in alertness or mood on visual analog scales. This disconnect between objective performance and subjective experience merits further investigation and has implications for medication adherence in clinical populations.

The study used sophisticated cognitive testing methods including the Sustained Attention to Response Task (SART) to measure response inhibition and sustained attention, and a delayed response task adapted from previous research to assess VS-WM. The primary outcome measure was the Balanced Integration Score (BIS), which combines speed and accuracy to control for speed-accuracy trade-offs. Notably, the study found no correlation between drug-induced parkinsonian symptoms and changes in response latency, suggesting that the cognitive effects were not simply due to motor slowing.

The research included two independent groups of healthy volunteers who received either amisulpride and placebo or aripiprazole and placebo for seven days each, with treatment order randomized and counter-balanced. After completing the first treatment period, participants entered a washout period before crossing over to the other treatment condition. Compliance was assessed with pill counts and blood sampling for drug levels.

Where Do We Go From Here?

Looking ahead, the researchers suggest several directions for future investigation, including testing whether these cognitive effects persist with longer treatment duration, evaluating whether similar effects occur in patients with schizophrenia and other disorders, and determining whether adaptations develop over time. There is also interest in exploring computational models to further understand how D2/D3 modulation affects decision thresholds during cognitive tasks.

Industry Context: This study comes at a time when the pharmaceutical industry is increasingly recognizing the importance of cognitive side effects in psychotropic medication development. With tens of millions of patients worldwide taking antipsychotics long-term, cognitive impairment represents a significant burden affecting functional outcomes and quality of life. The finding that even a partial agonist like aripiprazole produces similar cognitive effects to a full antagonist suggests that novel approaches beyond current D2/D3 receptor modulation strategies may be needed to truly address this unmet need. Companies developing next-generation antipsychotics will need to carefully evaluate cognitive effects using sensitive measures that can detect changes in response latency as well as accuracy.

Summary

A new study from a UK academic center has revealed that antipsychotic medications amisulpride and aripiprazole impair visuospatial working memory in healthy volunteers after seven days of administration. The double-blind, placebo-controlled crossover study found that both medications affected cognitive performance, particularly in terms of response times rather than accuracy. Contrary to previous assumptions, aripiprazole, a partial agonist, showed similar cognitive effects to amisulpride, a full antagonist. The research utilized sophisticated cognitive testing methods and demonstrated that these effects were not related to motor slowing. These findings have significant implications for pharmaceutical development and clinical practice, suggesting the need for novel approaches beyond current D2/D3 receptor modulation strategies.